All News

syringe, pill, DMARD, Treatment, therapy

Emerging and exciting treatments in RA: ACR22 preview

d Julian Segan, MBBS, BMedSc, FRACP

Rheumatoid arthritis treatment has come leaps and bounds in recent decades. Gone are the days of gold injections, chemical synovectomies, and physician-mandated bedrest (heaven forbid). Though the marketplace for RA treatments is becoming ever more crowded, there are still unmet needs.

Read Article
RA, hands, MCP, deformity

New 2022 EULAR Recommendations for the Management of Rheumatoid Arthritis

d Jack Cush, MD

The updated 2022 EULAR recommendations for the management of rheumatoid arthritis (RA) were initially presented by Dr. Josef Smolen at EULAR 2022, and are now in press delineating the most recent developments and perspectives in RA treatment.

Read Article
Convention2.jpg

AS, Lupus and Subclinical RA: What I'm looking forward to at ACR22

d Robert Chao, MD

As we approach ACR22, there are many things to be excited about, especially with the reintroduction of in-person attendance. My attention this year is in research being presented in these three areas: ankylosing spondylitis; lupus management and treatment; and, subclinical RA.

Read Article
pediatric.kid_.jpg

ACR22 Presents New Data on JIA Clinical Remission with Combo DMARDSs

d EurekAlert!

New research being presented this week at ACR Convergence 2022, demonstrated that polyarticular juvenile idiopathic arthritis patients were more likely to achieve clinical remission with a combination of conventional and biologic DMARDs compared with other consensus treatment plans by the Childhood Arthritis and Rheumatology Research Alliance (CARRA).

Read Article
guidelines.recommendations.jpg

Update: axSpA Recommendations

d EurekaAlert!

Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic musculoskeletal disease which can be managed with both pharmacological and non-pharmacological options. The joint ASAS-EULAR recommendations for axSpA were first developed in 2006, and last updated in 2016.

Read Article
FDA issues an Emergency Use Authorization (EUA) for anakinra (Kineret) to treat Hospitalized COVID-19+ Patients with pneumonia requiring supplemental O2 & ! risk for respiratory failure or increased suPAR levels https://t.co/t5gFULIhCH

Links:

Dr. John Cush RheumNow ( View Tweet)

Dr. Yuz Yusof will be covering #ACR22 as a RheumNow reporter again. He'll be sharing real-time coverage on SLE, auto-inflammatory and COVID. Follow @Yuz6Yusof! https://t.co/3rYlIrM54m
Dr. John Cush RheumNow ( View Tweet)
Chronic Pain increased from 2010-2919. A cross-sectional study of 46 420 respondents, shows nonpharmacologic Rx increased [aOR 2.72] & was greater than opioids for chronic, but not surgical pain. Govt policy & practice guidelines have helped. https://t.co/31oS0xWRMW https://t.co/IvkDRJQvT8

Links:

Dr. John Cush RheumNow ( View Tweet)
Sleep Habits study from NHANES - 9004 adults >20 yrs (2017-2020) finds mean sleep duration 7.6 hrs on workdays & 8.2 hrs on free days; 23% slept <7 hrs & 25% went to bed > midnight. Nearly 30% had trouble sleeping (daytime sleepiness 27%) https://t.co/Uc7nL4q3fm https://t.co/qvCwqbsez1

Links:

Dr. John Cush RheumNow ( View Tweet)
Follow RheumNow reporter, Dr. Eric Dein, for real-time #ACR22 coverage! https://t.co/NZkVd2A989
Dr. John Cush RheumNow ( View Tweet)
Our newest RheumNow reporter, Dr. Michael Putman , will be covering SLE and Vasculitis at #ACR22 this year. “Looking forward to seeing all my friends and colleagues in person!”-Dr. Putnam Follow him @EBRheum for real-time coverage! https://t.co/DpFa0zwzPX
Dr. John Cush RheumNow ( View Tweet)
QD Clinic - 1st Line Anakinra New-onset systemic JIA - how will you treat? #ACR22 https://t.co/cxG6ZcBXUv https://t.co/YCXD4z9BQ7

Links:

Dr. John Cush RheumNow ( View Tweet)
Video Telehealth Willingness Increased During Pandemic Americans’ willingness to use video telehealth has increased since the beginning of the pandemic, rising most sharply among Black Americans and people with less education, according to a new study. https://t.co/oi3C2A7yJt https://t.co/H8AhiXeU3r

Links:

Dr. John Cush RheumNow ( View Tweet)
#ACR22 Will Present New Recommendations for Integrative Approach to RA Treatment https://t.co/FI5k6LIKrO https://t.co/I0F1wJNBDc

Links:

Dr. John Cush RheumNow ( View Tweet)
Plaquenil (HCQ) reduces #SLE mortality. Metanalysis (21 studies, 26,037 pts). Pooled findings - HCQ significantly reduced SLE mortality (HR 0.46); HCQ also reduced mortality in SLE pts w/ renal (HR=0.43), & cardiopulmonary dz (HR=0.37) https://t.co/fsHaN8wR17 https://t.co/MW8cvavzBC

Links:

Dr. John Cush RheumNow ( View Tweet)
Opportunistic Infections with JAK inhibitors in RA Winthrop and colleagues have reviewed the occurrence of OIs associated with the use of JAK inhibitors in patients with RA, showing that Herpez zoster (HZ) was the most common OI reported. https://t.co/CtFcnHiWKS https://t.co/qKU51vLxaP

Links:

Dr. John Cush RheumNow ( View Tweet)
We're excited to have Dr. Aurelia Najm back as an #ACR22 RheumNow reporter! "I look forward to learning about developments in the field and finally meet with colleagues and collaborators from all over the world. " -Dr. Najm Follow @AurelieRheumo for real time #ACR22 coverage! https://t.co/o6Mhobt2BR
Dr. John Cush RheumNow ( View Tweet)
Dr. Robert Chao is back as a RheumNow reporter for a third year. "I’m looking forward to the exciting hybrid format of both in person and virtual meeting this year! " Follow @doctorRBC for real-time #ACR22 coverage! https://t.co/j6FNra7aZq
Dr. John Cush RheumNow ( View Tweet)
Join Dr. Jack Cush and Dr. Arthur Kavanaugh as they discuss, dissect and deliberate about data presented at the #ACR22 meeting in Philadelphia. https://t.co/STvWZMS7xS https://t.co/oQt3ZMyjEN

Links:

Dr. John Cush RheumNow ( View Tweet)
QD Clinic - Seropositive Arthralgia (abstract #1604) 42 yr old woman with +RF and Arthralgias only. How to treat? https://t.co/MgPFHa0CAd https://t.co/Aqlrc6rOSt

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×